Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cetuximab - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Cetuximab - Eli Lilly and Company

Alternative Names: Anti-EGFR monoclonal antibody 225; C 225; ch 225; Erbitux; IMC-C225; LY-2939777

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California
  • Developer Array BioPharma; Bristol-Myers Squibb; Celldex Therapeutics Inc; Centre Jean Perrin; Eli Lilly; Eli Lilly and Company; Fudan University; Merck KGaA; National Cancer Institute (USA); New York University School of Medicine; Novartis; Pfizer; Pierre Fabre; Radiation Therapy Oncology Group; Roche; UNICANCER; University of Michigan Comprehensive Cancer Center
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Squamous cell cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Head and neck cancer
  • Phase III Non-small cell lung cancer
  • Phase II Bladder cancer; Breast cancer; Gastric cancer; Malignant-mesothelioma; Rectal cancer; Squamous cell cancer
  • Phase I/II Adenoid cystic carcinoma; Solid tumours
  • Phase Unknown Oesophageal cancer
  • No development reported Pancreatic cancer; Prostate cancer

Most Recent Events

  • 20 Oct 2023 Updated efficacy and adverse event data from a phase II trial in squamous cell carcinoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 03 Apr 2023 Celldex Therapeutics terminates a phase II trial in Head and neck cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA due to sponsor decision based on emerging risk-benefit profile (NCT03254927)
  • 10 Nov 2022 Merck KGaA, Array BioPharma and Pierre Fabre completes the phase III BEACON CRC trial in Colorectal cancer (Second-line therapy or greater, Metastatic disease, Combination therapy) in Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czech Republic, Denmark, England, France, Germany, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Norway, Poland, Russia, Scotland, South Korea, Spain, Taiwan, Turkey, Ukraine, United Kingdom, USA (PO) (NCT02928224) (EudraCT2015-005805-35)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top